⌕
Ocular Therapeutix · OCUL · Nasdaq
Tenet 51 · Mixed
Compare
$6.02+0.17%At closeTenet 51 · Mixed
$6.02+0.01 (+0.17%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Ocular Therapeutix (OCUL) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue fell 18.5% in FY25, net margin −511.9%. Worth your attention in FY25: Share count (+127.9%) and Capex step-up ($12.0M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼18.5%
52.0
FY21→FY25CAGR +4.5%/yr
Net income ($M)▼37.4%
−265.9
FY21→FY25CAGR —
Free cash flow ($M)▼59.5%
−216.9
capex stepped upCAGR —
Diluted EPS▼16.4%
−1.42
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+127.9%

82.2mn → 187.2mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$12.0M

▲832% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)52.0Revenue−6.6COGS45.4Gross profit−197.1R&D−64.4SG&A−270.0Op income4.1Tax & other−265.9Net income

-512¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Over this window: gross 89.9% → 87.3%. Net margin -511.9% is below the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
50.452.063.758.451.543.5▼18.5%+4.5%
Cost of revenue
6.46.65.65.34.54.4▲16.9%+10.5%
Gross profit
44.045.458.153.247.039.1▼21.9%+3.8%
Research & development
245.9197.1127.661.153.550.1▲54.4%+40.8%
Selling, general & admin
78.764.460.733.932.231.9▲6.1%+19.2%
Total operating expenses
387.1315.4229.9135.5125.6117.2▲37.2%+28.1%
Operating incomefeeds ROC rank
−343.1−270.0−171.8−82.4−78.7−78.0▼57.2%—
Other income, net
16.24.0−21.71.67.671.5——
Pretax income
−326.8−266.0−193.5−80.7−71.0−6.6▼37.4%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−326.8−265.9−193.5−80.7−71.0−6.6▼37.4%—
Per share
Diluted EPSbuyback-sensitive
−1.44−1.42−1.22−1.02−0.97−0.98▼16.4%—
Diluted shares (mn)
225.52187.24158.2785.6082.6482.16▲18.3%+22.9%
Margins
Gross margin82nd pct in Healthcare
87.3%87.3%91.2%91.0%91.2%89.9%▼3.8pp−2.5pp
Operating margin
−680.9%−519.8%−269.6%−141.0%−152.7%−179.3%▼250.2pp−340.4pp
Net margin5th pct in Healthcare
−648.6%−511.9%−303.7%−138.1%−138.0%−15.1%▼208.2pp−496.8pp
† TTM = trailing four quarters through 2026-09-30.
FY12 – FY20 · 9 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 9 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-05 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Ocular Therapeutix's revenue last fiscal year?

Ocular Therapeutix reported revenue of $52.0M in fiscal 2025, down 18.5% from fiscal 2024.

What was Ocular Therapeutix's net income?

Ocular Therapeutix reported net income of −$265.9M in fiscal 2025, a net margin of −511.9%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.